|
|
Volumn 4, Issue 2, 2014, Pages 138-
|
|
FDA OK's iclusig's return to market
a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PONATINIB;
PROTEIN TYROSINE KINASE INHIBITOR;
ACUTE LYMPHOBLASTIC LEUKEMIA;
CHRONIC MYELOID LEUKEMIA;
DRUG EFFICACY;
DRUG MARKETING;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE PERSONNEL;
HUMAN;
NOTE;
VASCULAR DISEASE;
DRUG APPROVAL;
HUMANS;
IMIDAZOLES;
PYRIDAZINES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84896734338
PISSN: 21598274
EISSN: 21598290
Source Type: Journal
DOI: 10.1158/2159-8290.CD-NB2014-001 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|